Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alvaro Laureano

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Biotechnology Letters|January 19, 2018
A simple protocol for transfecting human mesenchymal stem cellsTalita Giacomet de Carvalho, Felipe Matheus Pellenz, Alvaro Laureano, et al.
Molecular Cancer Therapeutics|August 1, 2012
REST is a novel prognostic factor and therapeutic target for medulloblastomaPete Taylor, Jason Fangusaro, Veena Rajaram, et al.
Bone Marrow Research|January 14, 2014
Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell TransplantationBeatriz Stela Pitombeira, Alessandra Paz, Annelise Pezzi, et al.
Journal of Neuro-Oncology|April 11, 2019
Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRIBridget A Kennis, Keith A Michel, William B Brugmann, et al.
Journal of Neuro-Oncology|February 22, 2019
Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRIBridget A Kennis, Keith A Michel, William B Brugmann, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Biotechnology Letters|January 19, 2018
A simple protocol for transfecting human mesenchymal stem cellsTalita Giacomet de Carvalho, Felipe Matheus Pellenz, Alvaro Laureano, et al.
Molecular Cancer Therapeutics|August 1, 2012
REST is a novel prognostic factor and therapeutic target for medulloblastomaPete Taylor, Jason Fangusaro, Veena Rajaram, et al.
Bone Marrow Research|January 14, 2014
Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell TransplantationBeatriz Stela Pitombeira, Alessandra Paz, Annelise Pezzi, et al.
Journal of Neuro-Oncology|April 11, 2019
Correction to: Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRIBridget A Kennis, Keith A Michel, William B Brugmann, et al.
Journal of Neuro-Oncology|February 22, 2019
Monitoring of intracerebellarly-administered natural killer cells with fluorine-19 MRIBridget A Kennis, Keith A Michel, William B Brugmann, et al.
Pageof 1